Welcome to our dedicated page for Medifast SEC filings (Ticker: MED), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medifast, Inc. filings document the public-company disclosures of a NYSE-listed metabolic health and wellness business centered on its coach-guided lifestyle system. Form 8-K reports furnish quarterly and annual earnings releases that detail revenue, gross profit, active earning coach trends, liquidity, debt status and management commentary on the company's metabolic health strategy.
Proxy and current reports cover board elections, stockholder voting results, executive compensation, equity incentive plan amendments, leadership changes and material definitive agreements. Recent governance disclosures include a stockholder cooperation agreement, annual meeting matters and compensatory arrangements connected to executive transitions.
Director Andrea B Thomas of Medifast received 11,168 restricted stock units (RSUs) on June 25, 2025, as part of the Director's Deferred Compensation Plan. The RSUs were granted under the company's Amended and Restated 2012 Share Incentive Plan.
Key details of the transaction:
- RSUs were granted at $0 cost to the director
- Each unit represents one share of Medifast common stock
- Full vesting scheduled for June 25, 2026
- Following the transaction, Thomas owns 24,017.123 shares directly
This grant represents standard director compensation rather than an open market transaction. The filing was submitted by attorney-in-fact Jason L. Groves on June 26, 2025, within the required reporting timeframe.
Director Michael A. Hoer of Medifast received a significant equity grant of 11,168 restricted stock units (RSUs) on June 25, 2025, as part of the company's Director's Deferred Compensation Plan. The RSUs were granted at $0 cost and will fully vest on June 25, 2026.
Key details of the transaction:
- Each RSU represents the right to receive one share of Medifast common stock
- The grant was made under the Amended and Restated 2012 Share Incentive Plan
- Following the transaction, Hoer owns 26,139.473 shares directly
- The RSUs were granted in connection with annual director compensation
This Form 4 filing, signed by attorney-in-fact Jason L. Groves, indicates continued alignment of director interests with shareholders through equity-based compensation.
Medifast director Elizabeth A. Geary received 11,168 restricted stock units (RSUs) on June 25, 2025 as part of the company's Director's Deferred Compensation Plan. The RSUs were granted at $0 cost and will fully vest on June 25, 2026.
Key details:
- Each RSU represents the right to receive one share of Medifast common stock
- The grant was made under the Amended and Restated 2012 Share Incentive Plan
- Following the transaction, Geary directly owns 19,545 shares
- The RSUs were granted in connection with annual director compensation
This Form 4 filing indicates standard director equity compensation practices at Medifast, with a one-year vesting period for director RSU grants.
Medifast Director Jeffrey J. Brown reported significant stock acquisitions on June 25, 2025, through multiple transactions:
- Received 11,167.542 restricted stock units under the Director's Deferred Compensation Plan, which will fully vest on June 25, 2026
- Acquired 9,449.458 shares of common stock at $13.39 per share in lieu of cash compensation for director services
Following these transactions, Brown's total beneficial ownership includes:
- 38,577.647 shares held directly
- 4,232.967 shares held indirectly through the Jeffrey Brown Living Trust
The stock price was calculated using the 20-day moving average as of June 6, 2025. This Form 4 filing demonstrates significant insider accumulation of shares through compensation arrangements, suggesting continued alignment with shareholder interests.
Medifast, Inc. (NYSE: MED) filed an 8-K reporting the results of its 2025 Annual Meeting held on June 18, 2025.
Equity plan expansion: Shareholders approved an amendment to the Amended and Restated 2012 Share Incentive Plan, authorizing an additional 550,000 common shares for future equity awards. The plan became effective immediately and its full text is attached as Exhibit 10.1.
Board elections: All seven incumbent directors were re-elected. Support ranged from 90.3 % (Andrea B. Thomas) to 97.2 % (Jeffrey J. Brown) of votes cast, with 2.09 million broker non-votes recorded for each nominee.
Auditor ratification: RSM US LLP was ratified as independent auditor for FY 2025 with 99.2 % of votes in favor (8,225,570 for / 39,619 against).
Say-on-pay advisory vote: Compensation for named executive officers passed but with a modest margin—3,585,469 for vs. 2,477,849 against (59.1 % support, excluding abstentions).
Plan approval vote: The amended share incentive plan itself received 5,518,075 for vs. 664,416 against (88.2 % support, excluding abstentions).
No other material transactions, earnings data, or financial statements were disclosed.